AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Ubiquitin carboxyl-terminal hydrolase 46

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P62068

UPID:

UBP46_HUMAN

Alternative names:

Deubiquitinating enzyme 46; Ubiquitin thioesterase 46; Ubiquitin-specific-processing protease 46

Alternative UPACC:

P62068; B7Z3Y7; B7Z675; B7Z7S3; G8ACC7; Q80V95; Q9H7U4; Q9H9T8

Background:

Ubiquitin carboxyl-terminal hydrolase 46, known alternatively as Deubiquitinating enzyme 46, Ubiquitin thioesterase 46, and Ubiquitin-specific-processing protease 46, plays a pivotal role in neural behavior. It regulates GABA action through the deubiquitination of GAD1/GAD67, enhancing its activity in partnership with WDR48. Its specificity excludes monoubiquitinated FANCD2 deubiquitination.

Therapeutic significance:

Understanding the role of Ubiquitin carboxyl-terminal hydrolase 46 could open doors to potential therapeutic strategies, especially in neurological disorders where GABA signaling is implicated.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.